0001104659-20-071368.txt : 20200710 0001104659-20-071368.hdr.sgml : 20200710 20200609160219 ACCESSION NUMBER: 0001104659-20-071368 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 CORRESP 1 filename1.htm

SELLAS Life Sciences Group, Inc.

15 West 38th St., 10th Floor

New York, New York 10018

 

June 9, 2020

 

Via EDGAR

 

Sonia Bednarowski

United States Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.
Washington, D.C. 20549

 

Re: SELLAS Life Sciences Group, Inc.
  Registration Statement on Form S-1  
  File No.  333-238799
  Acceleration Request

 

Dear Ms. Bednarowski,

 

Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-238799), so that it may become effective at 4:00 p.m. (Washington, D.C. time) on Thursday, June 11, 2020, or as soon thereafter as practicable.

 

Please call Daniel A. Bagliebter, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any comments or questions regarding the Registration Statement.

 

 

  Very truly yours,  
     
  SELLAS Life Sciences Group, Inc.
     
  /s/ Angelos M. Stergiou  
  By:  Angelos M. Stergiou, M.D., Sc.D., h.c.
  Its:  President and Chief Executive Officer

 

cc: Barbara A. Wood, SELLAS Life Sciences Group, Inc.
  Daniel A. Bagliebter, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.